Eli Lilly and Company (NYSE:LLY) Shares Down 1.4% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s stock price traded down 1.4% on Tuesday . The stock traded as low as $1,071.60 and last traded at $1,064.5180. 2,689,714 shares changed hands during trading, a decline of 13% from the average session volume of 3,100,566 shares. The stock had previously closed at $1,079.9610.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark is now covering Eli Lilly’s full obesity medicine portfolio, giving Foundayo and Zepbound broader access across all three of the largest U.S. pharmacy benefit managers and improving the company’s commercialization outlook.
• Positive Sentiment: Lilly announced new data presentations for its hematology franchise at the 2026 European Hematology Association meeting, including Phase 3 BRUIN CLL-322 results for Jaypirca and early clinical data from assets tied to recent acquisitions, reinforcing pipeline momentum.
• Positive Sentiment: The company reported a licensing deal with Hanmi for sonefpeglutide and a collaboration with Haisco, adding more pipeline optionality and showing Lilly is continuing to invest aggressively in future growth areas.
• Positive Sentiment: Late-stage Retevmo data showed a meaningful reduction in lung cancer recurrence risk, which could support label expansion and add another incremental growth opportunity.
• Neutral Sentiment: Several articles highlighted Lilly as a top stock pick and compared its growth profile to high-momentum megacaps, which reflects strong investor sentiment but does not change fundamentals directly.
• Neutral Sentiment: One report noted that a competing weight-loss pill from Novo Nordisk still leads in prescriptions, suggesting the GLP-1 race remains highly competitive even as Lilly’s launch gains traction.
• Negative Sentiment: A separate commentary argued that an ETF used to play the pharma sector is unattractive because of its weaker holdings, which is not a direct hit to Lilly but reflects that investors may prefer Lilly alone over broader pharma exposure.
• Negative Sentiment: Viking Therapeutics may have a near-term catalyst that could pressure expectations around the future weight-loss pill market, creating some competitive overhang for Lilly and Novo Nordisk.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their target price for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Guggenheim restated a “buy” rating and issued a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. BMO Capital Markets restated an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Morgan Stanley restated an “overweight” rating and issued a $1,344.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market cap of $1.00 trillion, a price-to-earnings ratio of 37.82, a P/E/G ratio of 1.21 and a beta of 0.53. The firm has a fifty day simple moving average of $959.18 and a two-hundred day simple moving average of $1,010.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Institutional Trading of Eli Lilly and Company

Institutional investors and hedge funds have recently made changes to their positions in the business. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth $25,000. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in shares of Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares during the last quarter. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $30,000. Finally, 10Elms LLP increased its holdings in shares of Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.